REGINfo: Sanofi-Aventis - Pharmacie - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
> TA 25
Israel - TA 25
- ALONY HETZ
- AZRIELI GROUP
- BAZAN
- BEZEQ
- DELEK DRILLIN
- DISCOUNT
- ELBIT SYSTEMS
- FIBI BANK
- GAZIT GLOBE
- HAREL
- ICL
- IFF
- ISRAEL CORP
- LEUMI
- MAZOR ROBOTICS
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- ORMAT
- PAZ OIL
- PERRIGO
- POALIM
- SHUFERSAL
- SODASTREAM
- STRAUSS GROUP
- TEVA
- TOWER JAZZ

Europe

COMPANY SEARCH RESULT

$Sanofi-Aventis: Click to view the issuer\'s details$

Last update : 13/03/2018 >View issuer details

2019.02.12 | 18:00 | Share History / Voting Rights and Number of Shares

puce Information concerning the total number of voting rights and shares - HTML (w)

2019.02.12 | 18:00 | Share History / Voting Rights and Number of Shares

puce Informations relatives au nombre total de droits de vote et d'actions - HTML (w)

2019.02.12 | 07:00 | Permanent Information Releases / Appointments

puce Sanofi appoints Ameet Nathwani Chief Digital Officer - HTML (w)

2019.02.12 | 07:00 | Permanent Information Releases / Appointments

puce Sanofi nomme Ameet Nathwani au poste de Chief Digital Officer - HTML (w)

2019.02.07 | 07:30 | Permanent Information Releases / Sales and Revenues

puce Sanofi delivers 2018 business EPS growth of 5.1% at CER - HTML (w)

2019.02.07 | 07:30 | Permanent Information Releases / Sales and Revenues

puce Sanofi annonce une croissance du BNPA des activités 2018 de 5,1% à TCC - HTML (w)

2019.02.06 | 22:00 | Permanent Information Releases / Appointments

puce Sanofi's Board of Directors notes the resignation of Christian Mulliez and co-opts Christophe Babule as Director - HTML (w)

2019.02.06 | 22:00 | Permanent Information Releases / Appointments

puce Le Conseil d'administration de Sanofi prend acte de la démission de Christian Mulliez et coopte Christophe Babule en tant que nouvel administrateur - HTML (w)

2019.02.06 | 17:43 | Permanent Information Releases / General Company News

puce Sanofi: FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP) - HTML (w)

2019.02.06 | 17:43 | Permanent Information Releases / General Company News

puce Sanofi : La FDA approuve Cablivi® (caplacizumab-yhdp), le premier médicament à base de Nanobody® pour le traitement du purpura thrombotique thrombocytopénique (PTT) acquis de l'adulte - HTML (w)

2019.02.05 | 07:00 | Permanent Information Releases / General Company News

puce Sanofi : Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma - HTML (w)

2019.02.05 | 07:00 | Permanent Information Releases / General Company News

puce Sanofi : L'essai de phase III consacré à l'isatuximab a atteint son critère d'évaluation principal de prolongation de la survie sans progression chez des patients atteints d'un myélome multiple ré... - HTML (w)

2019.02.04 | 07:00 | Permanent Information Releases / General Company News

puce Sanofi: CHMP recommends approval of Praluent® (alirocumab) to reduce cardiovascular risk in people with established atherosclerotic cardiovascular disease - HTML (w)

2019.02.04 | 07:00 | Permanent Information Releases / General Company News

puce Sanofi : Le CHMP recommande l'approbation de Praluent® (alirocumab) pour la réduction du risque cardiovasculaire chez les personnes atteintes de maladie cardiovasculaire athéroscléreuse établie - HTML (w)

2019.01.30 | 15:00 | Permanent Information Releases / General Company News

puce Sanofi: Fexinidazole, the first all-oral treatment for sleeping sickness, approved in Democratic Republic of Congo - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 2628